摘要
目的:探讨人canstatin基因对人肝癌移植瘤模型的抑制作用.方法:应用人肝癌细胞株SMMC-7721建立移植瘤模型.将裸鼠随机分成PBS组、空载体组和载体治疗组(腺病毒载体AdCan),两次注射.治疗期间测量皮下移植瘤的长径和短径;30d后处死裸鼠,取肿瘤行常规病理切片,观察肿瘤组织坏死情况;检测肿瘤组织中caspase-3,Flk-1的表达.结果:完成注射治疗后第3日,AdCan基因治疗组肿瘤体积显著小于其余两组;治疗期间,HE染色显示AdCan基因治疗组坏死最明显;AdCan基因治疗组caspase-3表达高于空载体组和对照组;canstatin基因治疗组Flk-1的表达低于空载体组和对照组.结论:人canstatin基因对肝癌移植瘤的生长具有抑制作用,作用机制可能是降低Flk-1的表达进而抑制肿瘤的血管生成,抑制肿瘤的生长.
AIM ：To investigate the anti-tumor effects of canstatin gene on human liver carcinoma（ SMMC-7721 ）. METHODS： Tumor xenografts were induced by injection of 1 × 10^7 SMMC- 7721 cells into the left axilla of BALB/c nude mice. The animals were randomized into 3 groups （Adcan, AdGFP and PBS ）. During the treatment period, the size of tumors was measured with caliper every 3 d. At the end of the experiment（day 30）, all the tumors were resected and both routine pathology and immunohisto- chemical examinations were performed to observe the drug toxicity and the expression of Flk-1 and caspase-3. RESULTS： In canstatin group, the tumors were significantly suppressed in com- parison with those in control groups. The HE staining showed many large necrotic regions in tumors from each group, especially in the Ad-canstatin-treated group. The expression of Flk-1 in tumor cell membrane decreased in mice treated with canstatin. The expression of caspase-3 in tumor cell membrane increased in mice treated with canstatin. CONCLUSION： Canstatin inhibits the growth of human primary liver carcinoma by restraining the angiogenesis of tumors.
出处
《第四军医大学学报》
CAS
北大核心
2009年第10期910-912,共3页
Journal of the Fourth Military Medical University
